Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) have received an average rating of “Hold” from the nine analysts that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $15.75.

A number of research firms have commented on ABEO. BidaskClub upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. Mizuho restated a “hold” rating and set a $4.00 price target on shares of Abeona Therapeutics in a research report on Monday, September 23rd. Maxim Group downgraded shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Cantor Fitzgerald downgraded shares of Abeona Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, August 12th. Finally, Royal Bank of Canada dropped their price target on shares of Abeona Therapeutics to $16.00 and set a “positive” rating on the stock in a research report on Tuesday, August 13th. They noted that the move was a valuation call.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of Abeona Therapeutics by 21,590.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,477 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Abeona Therapeutics by 434.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 7,088 shares in the last quarter. Ellington Management Group LLC bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $50,000. Trexquant Investment LP bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $53,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $59,000. Institutional investors and hedge funds own 58.71% of the company’s stock.

Shares of ABEO stock traded down $0.02 during midday trading on Thursday, reaching $2.19. 15,097 shares of the company were exchanged, compared to its average volume of 729,164. Abeona Therapeutics has a 12 month low of $1.46 and a 12 month high of $10.88. The company has a market cap of $112.20 million, a P/E ratio of -1.85 and a beta of 1.95. The company’s 50 day moving average price is $2.48 and its two-hundred day moving average price is $4.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.54 and a current ratio of 2.54.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). As a group, sell-side analysts predict that Abeona Therapeutics will post -1.7 earnings per share for the current year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Article: How to execute a trade ex-dividend strategy?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.